Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-1 in moderate to severe active ulcerative colitis
CTR20232947Phase 3Completed
- Sponsor
- Abivax
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Obefazimod with Placebo (2 arms). Primary endpoint: Clinical remission based on modified Mayo score. Started Apr 2024; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20232947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232947.